Pharmaceuticals (Sep 2020)

Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?

  • Aleksandra Hecel,
  • Małgorzata Ostrowska,
  • Kamila Stokowa-Sołtys,
  • Joanna Wątły,
  • Dorota Dudek,
  • Adriana Miller,
  • Sławomir Potocki,
  • Agnieszka Matera-Witkiewicz,
  • Alicia Dominguez-Martin,
  • Henryk Kozłowski,
  • Magdalena Rowińska-Żyrek

DOI
https://doi.org/10.3390/ph13090228
Journal volume & issue
Vol. 13, no. 9
p. 228

Abstract

Read online

Zn(II) is an inhibitor of SARS-CoV-2′s RNA-dependent RNA polymerase, and chloroquine and hydroxychloroquine are Zn(II) ionophores–this statement gives a curious mind a lot to think about. We show results of the first clinical trials on chloroquine (CQ) and hydroxychloroquine (HCQ) in the treatment of COVID-19, as well as earlier reports on the anticoronaviral properties of these two compounds and of Zn(II) itself. Other FDA-approved Zn(II) ionophores are given a decent amount of attention and are thought of as possible COVID-19 therapeutics.

Keywords